---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-25-000066"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2025-04-29T23:59:59+00:00"
generated_at: "2026-05-23T03:52:06.736568+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# USPTO invalidates all challenged claims of Pharmacyclics patent in BeiGene's BRUKINSA® PGR

## Summary
- USPTO Final Written Decision invalidates all claims of Pharmacyclics' U.S. Patent No. 11,672,803 challenged by BeiGene in post-grant review.
- Patent is part of infringement lawsuit against BeiGene's BTK inhibitor BRUKINSA® (zanubrutinib) filed by Pharmacyclics in 2023.
- BeiGene filed PGR petition on November 1, 2023; USPTO decision is appealable by Pharmacyclics.

## SEC filing metadata
- accession: 0001651308-25-000066
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2025-04-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130825000066/0001651308-25-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130825000066/bgne-20250429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-25-000066
- JSON: https://secwatch.observer/filing/0001651308-25-000066.json
- Plain text: https://secwatch.observer/filing/0001651308-25-000066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.